Back to search

Article

Natural history model predicts benefits associated with screening for lung cancer by detecting circulating tumor DNA

2023-08-10

Abstract excerpt

<title>Abstract</title> <p>Current US screening guidelines recommend low dose computed tomography (LDCT) scans for high-risk individuals of lung cancer, however, only 13% of the eligible population adhere to the recommendation. Using circulating tumor DNA (ctDNA) as a blood-based cancer biomarker for screening may increase the adherence to screening programs while simultaneously decreasing radiation exposure and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cdf12712-4605-59b2-a02e-537522b60eec
DOI
10.21203/rs.3.rs-3226127/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Natural history model predicts benefits associated with screening for lung cancer by detecting circulating tumor DNADOI 10.21203/rs.3.rs-3226127/v1
Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity
The BREATHE project: An observational prospective cohort integrating clinical data, blood samples and tumor tissue from newly diagnosed patients with lung cancerSemantic proximity
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.Semantic proximity
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.Semantic proximity
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Semantic proximity
Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSemantic proximity
Multi-Center Study of Resectable Lung Lesions by Ultra-Deep Sequencing of Targeted Genes in Plasma Cell-Free DNA to Assess Nodule Malignancy and Detect Lung CancersSemantic proximity
Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directionsSemantic proximity
Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNASemantic proximity
Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamicsSemantic proximity
Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model.Semantic proximity
Early ctDNA kinetics as a dynamic biomarker of cancer treatment responseSemantic proximity
Select a neighboring publication to make it the new centre.